Date: 2016-09-20
Type of information: Grant
Company: CxCOG consortium (Theranexus, Synerlab Developpement, Lille University Hospital) (France)
Investors: FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France
Amount: € 3.2 million ($ 3.6 million)
Funding type: grant
Planned used: The project CX?COG will be carried out by Theranexus in collaboration with the team of Prof. Régis Bordet (Lille University, Lille University Hospital, Inserm) and the company Synerlab. The project concerns the pharmaceutical formulation development and clinical validation of the efficacy of THN201 in the treatment of neurocognitive impairment particularly associated with Alzheimer's disease. The goal of the project launched by Theranexus is to demonstrate the clinical performance of an innovative proprietary combination of donepezil and an existing medication that improves the efficacy of this drug fivefold. The outcome sought from this development is to rapidly strengthen the therapeutic arsenal by inducing a 12 to 18 The partners of the CxCOG consortium now plan to initiate at the earliest possible time the foreseen characterisation work in in vivo models and, in healthy subjects, of the tolerance and pharmacokinetic parameters of THN201. Work towards developing an innovative formulation for the product will also be carried out alongside these activities. Once accomplished, these tasks should make it possible to launch a clinical proof?of?concept study within 15 months. The study itself should last 15 months as well.
month delay in cognitive decline and placement in a care facility among patients affected by neurocognitive
impairment. Project CX?COG, which is being coordinated by Theranexus, covers the design and development of combinations of existing medications that have been proven to improve the efficacy of certain neurological and psychiatric treatments.
Others: * On September 20, 2016, Theranexus announced that it has received funding from the FUI (French Inter?ministry Fund) for its project CX?COG (FUI AAP22) which has been approved by the competitiveness clusters Lyonbiopôle and Atlanpôle Biothérapies.
Therapeutic area: Neurodegenerative diseases
